Warning: The NCBI web site requires JavaScript to function. more...
Fetching bibliography...
Generate a file for use with external citation management software.
The comparative disposition and metabolism of dolutegravir, a potent HIV-1 integrase inhibitor, in mice, rats, and monkeys.
Moss L, Wagner D, Kanaoka E, Olson K, Yueh YL, Bowers GD.
Xenobiotica. 2015 Jan;45(1):60-70. doi: 10.3109/00498254.2014.942409. Epub 2014 Jul 18.
Similar articles
In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor.
Reese MJ, Savina PM, Generaux GT, Tracey H, Humphreys JE, Kanaoka E, Webster LO, Harmon KA, Clarke JD, Polli JW.
Drug Metab Dispos. 2013 Feb;41(2):353-61. doi: 10.1124/dmd.112.048918. Epub 2012 Nov 6.
Renoprotective action of a matrix metalloproteinase inhibitor in progressive mesangioproliferative nephritis.
Kuroda T, Masui M, Notoya M, Ito M, Tamura Y, Okamoto H, Kanaoka E, Shinosaki T.
Nephron Extra. 2012 Jan;2(1):133-46. doi: 10.1159/000338801. Epub 2012 May 26.
Role of Na+/L-carnitine transporter (OCTN2) in renal handling of pivaloylcarnitine and valproylcarnitine formed during pivalic acid-containing prodrugs and valproic acid treatment.
Ohnishi S, Okamura N, Sakamoto S, Hasegawa H, Norikura R, Kanaoka E, Takahashi K, Horie K, Sakamoto K, Baba T.
Drug Metab Pharmacokinet. 2008;23(4):293-303.
Continuous release of interleukin-2 from liposomal IL-2 (mixture of interleukin-2 and liposomes) after subcutaneous administration to mice.
Kanaoka E, Takahashi K, Yoshikawa T, Jizomoto H, Nishihara Y, Hirano K.
Drug Dev Ind Pharm. 2003 Nov;29(10):1149-53.
A new generic column switching system for quantitation in cassette dosing using LC/MS/MS.
Ohkawa T, Ishida Y, Kanaoka E, Takahashi K, Okabe H, Matsumoto T, Nakamoto S, Tamada J, Koike M, Yoshikawa T.
J Pharm Biomed Anal. 2003 Apr 10;31(6):1089-99.
A significant enhancement of therapeutic effect against hepatic metastases of M5076 in mice by a liposomal interleukin-2 (mixture).
Kanaoka E, Takahashi K, Yoshikawa T, Jizomoto H, Nishihara Y, Uchida N, Maekawa R, Hirano K.
J Control Release. 2002 Aug 21;82(2-3):183-7.
Microemulsion formulation for enhanced absorption of poorly soluble drugs. I. Prescription design.
Kawakami K, Yoshikawa T, Moroto Y, Kanaoka E, Takahashi K, Nishihara Y, Masuda K.
J Control Release. 2002 May 17;81(1-2):65-74.
A novel and simple type of liposome carrier for recombinant interleukin-2.
J Pharm Pharmacol. 2001 Mar;53(3):295-302.
Stabilization of aerosolized IFN-gamma by liposomes.
Kanaoka E, Nagata S, Hirano K.
Int J Pharm. 1999 Oct 25;188(2):165-72.
pH-sensitive liposomes composed of tocopherol hemisuccinate and of phosphatidylethanolamine including tocopherol hemisuccinate.
Jizomoto H, Kanaoka E, Hirano K.
Biochim Biophys Acta. 1994 Aug 4;1213(3):343-8.
Gelatin-acacia microcapsules for trapping micro oil droplets containing lipophilic drugs and ready disintegration in the gastrointestinal tract.
Jizomoto H, Kanaoka E, Sugita K, Hirano K.
Pharm Res. 1993 Aug;10(8):1115-22.
Filters: Manage Filters